CLINICAL_TRIALS trial_result · 2025-06-06

Clinical Trial Update: A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR) [Phase 2]

Phase 2 study evaluating nivolumab as pre- and post-operative therapy for metastatic renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED